In recent years, with the fierce competition for the homogenization of domestic pharmaceutical equipment, some local pharmaceutical equipment enterprises with strength are accelerating their development into
overseas markets.
Pharmaceutical equipment (Image source: Pharmaceutical Network)
At the end of August, Chutian Technology introduced the operation of the first half of 2022 in the disclosed research activity information, achieving operating income of 2.
870 billion yuan, an increase of 20% year-on-year; Attributable net profit was 299 million, an increase of 27%
year-on-year.
The reason why it can achieve such results, Chutian Technology mentioned 5 major reasons, one of which is due to the international business began to exert force
.
It said that at present, the company's international business sales and service personnel have increased to more than 300 people, and in key countries and regions to establish sales and service centers, vigorously explore overseas markets, and continuously improve the company's international sales
.
In October 2020, Chutian expanded its channels by completing the acquisition of The German company Romaco, and its overseas competitiveness increased year by year, but in the first half of this year, the company's overseas sales growth rate and gross profit margin growth rate declined
.
The overall international business in the first half of the year was not as expected
The overall international business in the first half of the year was not as expected
In the interactive part of the survey, the company replied to the reasons for the decline in overseas sales growth and gross profit margin growth in the first half of the year, saying that it was mainly caused by
Romaco's revenue not meeting expectations.
He also said that Romaco has sufficient orders in hand and is confident of achieving its performance commitments at the time of mergers and acquisitions
throughout the year.
Romaco is a company specializing in the manufacture of solid pharmaceutical processing and packaging equipment with five production sites in Europe and a portfolio of 7 brands
, Including Noack, Sieble, Macofar, Promatic, Kilian, Innojet and Tecpharm.
According to reports, the international business of Chutian Technology includes all the business of The German Romaco and the export business
of the domestic main company.
In the first half of the year, the export business of domestic companies increased year-on-year, and Romaco Company was affected by the epidemic and other factors, the delivery cycle slowed down, the revenue did not meet expectations, and the amortization of fixed expenses became higher, making the overall performance less than expected
.
According to the 2022 semi-annual report, during the reporting period, Romaco Group achieved operating income of 531 million yuan in the first half of the year, down 23.
34% from the same period of the previous year, and the net profit loss was 47.
53 million yuan, down 405.
08%
from the same period of the previous year.
According to the Performance Commitment Compensation Agreement signed by the two parties when Chutian Technology acquired ROMACO, the forecast net profit of Romaco in 2020, 2021 and 2022 is not less than 7 million euros, 8.
1 million euros and 9 million euros
respectively.
Some analysts believe that Romaco's brand influence in the field of solid dosage is strong, coupled with the influence of expanding channels, it is expected that with the normal delivery cycle in the future, it will maintain long-term stable growth
.
Strive to surpass domestic revenue from overseas business around 2030
Strive to surpass domestic revenue from overseas business around 2030
Judging from the progress of Chutian Technology's overseas business expansion, the company has gradually expanded from the cautious promotion in previous years to the vigorous expansion of overseas markets in the past two years, and has established sales and service centers
in many countries and regions around the world.
Behind the transformation is the improvement of the quality of some of the company's products, as well as the ability to innovate, deliver, and quality assurance
.
Chutian Technology has two major domestic and international sales service systems, and the current domestic sales scale is greater than that of the international
.
However, the company is actively expanding the international market, according to the company's plan, 2023 overseas sales on the basis of this year to increase by 30%-50%, and expect the company to achieve overseas business income accounted for about 50% of the total revenue around 2025, around 2030, strive to overseas business income more than domestic business income
.
Industry analysts believe that in recent years, due to the impact of environmental and other factors, the production, delivery and operation of overseas pharmaceutical equipment enterprises have been affected, coupled with the rise in energy prices, it is expected that it will be an opportunity for the import substitution of domestic pharmaceutical machinery enterprises
.
With the fierce homogenization of the domestic pharmaceutical equipment market, enterprises with strength can also use the layout of overseas markets to bring new growth points
to the company's performance.
At present, not only Chutian Technology, Dongfulong recently released the investor relations activity record table also conveyed the determination to actively layout the international market, which said that "at present, the company's product line has reached the full regional coverage, and the international product line is becoming increasingly rich, so the growth ratio of the company's international revenue will gradually increase
in the future.
" ”
